With covalent meds abuzz, RA Capital and Novartis lead $56M seed round for new startup

Seeing the successes of other covalent medicines companies, a group of blue-chip investors is lining up to take the next shot on goal.

RA Capital, typically known for its late-stage and crossover investments, is getting in on the ground floor at Hyku Biosciences, a new biotech that emerged from stealth…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks